ASCO 2023 | THOR: erdafitinib in advanced or metastatic urothelial cancer and FGFR alterations

Daniel Petrylak, MD, Yale School of Medicine, New Haven, CT, discusses the Phase III THOR (NCT03390504) study evaluating erdafitinib versus chemotherapy in patients with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor (FGFR) alterations. The study included 266 patients randomized to receive erdafitinib or investigator’s choice of chemotherapy (docetaxel or vinflunine). The primary endpoint of overall survival (OS) was significantly improved in the erdafitinib group, with a 36% reduction in the risk of death compared to chemotherapy. Erda also showed significant improvements in progression-free survival (PFS) and objective response rate (ORR) compared to chemotherapy. The safety profile of erdafitinib was consistent with previous findings. These results support the use of erdafitinib in patients with FGFR-altered mUC after PD-(L)1 treatment. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.